Q-omics provides the consensus-scored SAR1B profile across patient tissues and cancer cell-line models. SAR1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SAR1B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SAR1B RNA expression shows 20,310 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where SAR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAR1B survival associations across molecular data types. SAR1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAR1B RNA expression–survival associations across cancer types. High SAR1B expression shows unfavorable associations in KICH, UVM, HNSC, ESCA and LGG, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SAR1B RNA expression.
This table summarizes SAR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SAR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAR1B shows lower tumor expression in HNSC, COAD, LUSC and THCA and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher SAR1B RNA expression in tumor versus normal tissue (log2 FC = +0.334, t-test p < 0.001).
This table shows molecular features associated with SAR1B in patient tissues and cancer cell lines. In patient samples, SAR1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SAR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
